Digital Medicine Society (DiMe)’s Post

The FDA approves dozens of new therapeutics every year, along with new uses for familiar drugs. If you’re a life or health #underwriter, you need to know what they imply for #riskassessment. Our clinical team has your back. They’ll keep you up to speed on new drugs and their #mortality implications in this regularly updated feature, starting with a review of new treatments for post-partum depression, heart failure, and Alzheimer’s disease from Kimberly Sapre, DMSc, PA-C, CAQ-EM, DFAAPA.

FDA Approves Ocrevus Zunovo for 2 Forms of Multiple Sclerosis: The approval marks the first and only twice yearly, health care professional-administrated injection for both forms of multiple sclerosis (MS). #finance #pharmacy #lifesciences

🔬 Exciting Updates in Alzheimer's Research! 🔬 In a surprise move, the FDA has delayed its decision on Eli Lilly’s Alzheimer’s drug, donanemab, and plans to convene an advisory committee for further review. At Synergy Healthcare, we're closely following this development as it underscores the importance of rigorous evaluation in advancing treatments for neurodegenerative diseases. Lilly's press release highlights the FDA's additional inquiries into safety, clinical trial design, and patient stratification, reflecting the thoroughness of the regulatory process. While this delay may raise questions, it demonstrates the FDA's commitment to ensuring the safety and efficacy of new treatments. Advisory committee meetings are integral to evaluating the relative benefits and risks of novel therapies. Despite the delay, Lilly remains optimistic, emphasizing that this doesn’t alter their financial outlook for 2024. This development underscores the complexity of Alzheimer's research and the need for tailored approaches in clinical trials. We remain committed to being a premier site for metabolic and neurological disease trials, contributing to groundbreaking advancements in healthcare. #AlzheimersResearch #ClinicalTrials #NeurologicalHealth #FDAApproval #SynergyHealthcare #MedicalResearch #Innovation #PatientCare #HealthcareAdvancements 🔗 https://lnkd.in/ejay6mMX

Comparative Analysis of #Opioids and #Cannabis for Chronic Non-Cancer #Pain   Let’s start from the conclusion: “Cannabis for medical use may be similarly effective and result in fewer discontinuations than opioids for chronic non-cancer pain”.   This is the conclusion of a recent systematic review and network meta-analysis which delves into the comparative #benefits and #harms of opioids and cannabis for medical use in managing chronic non-cancer pain. Spanning 90 trials with 22,028 patients, the findings offer important insights.   ·     Opioids show moderate-certainty evidence of providing slight improvements in pain, physical functioning, and sleep quality compared to placebo. ·     Cannabis for medical use exhibits low to moderate-certainty evidence, suggesting similar effects to opioids against a placebo. ·     Neither opioids nor cannabis demonstrate superiority to placebo for role, social, or emotional functioning (high to moderate certainty). ·     Moderate-certainty evidence indicates little difference between cannabis and opioids in terms of physical functioning. ·     Cannabis users experience fewer discontinuations due to adverse events compared to opioid users. ·     Low-certainty evidence suggests minimal difference between cannabis and opioids in pain relief and sleep quality.   This analysis indicates that cannabis for medical use might offer comparable effectiveness to opioids for chronic non-cancer pain, with the added benefit of fewer discontinuations due to adverse events.   For those interested in the role of Medical Cannabis in chronic pain management and beyond, our #handbook, "Principles of Clinical Cannabinology," awaits an exploration. Comprehensive and insightful, it encapsulates everything you need to deepen your understanding: https://lnkd.in/debSUPpQ   Yours in Science, Cannabiscientia SA

Meet the company behind the S.T. Genesis and learn how we’re changing the way people overcome addiction. Speranza Therapeutics distributes and clinically supports innovative drugs and medical devices requiring FDA approval or clearance. We prioritize patients whose chronic illnesses and debilitating conditions are not being effectively addressed. Our mission statement is to remove the inherent challenges in delivering treatment to patients in need through proven, clinically effective therapeutics and technology. That is why Speranza Therapeutics has teamed up with a major pharmacy company to get the S.T. Genesis to people who need it most. The S.T. Genesis is a game-changer when it comes to addiction. Find out how at our website. Join the fight against addiction with Speranza Therapeutics #recoveryispossible #addictionrecovery #addictionsupport #addictionhelp #opioidaddiction #endthestigma #mentalhealthsupport #detoxwithoutfear

"The respective trajectories of two medications – one that helps obese people lose weight, the other highly effective at preventing heart attacks and strokes – illustrate the forces driving biomedical innovation in the United States... GLP-1 drugs are here to stay. Unfortunately, their high cost and popularity have put state health plans in a bind. An estimated two million Americans have turned to compounding pharmacies for inexpensive versions of semaglutide and tirzepatide, the active ingredients in Novo Nordisk and Eli Lilly’s drugs. This is legal under FDA guidelines when a brand-name drug is in shortage. As for the polypill, perhaps the rising toll of cardiovascular disease in the U.S. and globally will prompt reconsideration of its potential. In a Washington Post op-ed earlier this year, former CDC Director Tom Frieden wrote, 'Hypertension, the ‘silent killer,’ is the deadliest but most neglected and widespread pandemic of our time, killing more than 10 million people a year worldwide' In August, an American College of Cardiology report noted 'persistent and tragic inequities' in cardiovascular care among Black Americans...the report’s senior author observed that 'Black Americans, because of their higher cardiovascular mortality rates compared with white Americans, have suffered almost 800,000 excess deaths, which translates to about 24 million additional years of life lost between 2000 and 2022. This staggering figure highlights the critical need for systemic changes in addressing cardiovascular inequities.' The polypill could play a key role in solving these challenges." #Innovation #GLP1" #Polypill https://lnkd.in/egnqVzJx

You may have heard about #Leqembi, the latest FDA-approved breakthrough in #Alzheimers treatment. Anyone with early-stage #Alzheimers can get a prescription—but even with #Medicare Part B coverage, not everyone can afford it. Here's what you and your community need to know about the cost, access, and effectiveness of this drug.👇 #AlzheimersAndBrainAwarenessMonth https://lnkd.in/ei7uJwXP

Exciting and important news that another treatment option is now available for the treatment of serious mental illness. Rejoyn - an FDA-approved prescription digital therapeutic - another digital health first for Otsuka! #digitalhealth #PDT #digitaltherapeutic #BREAKING Otsuka Pharmaceutical Co., Ltd., and Click Therapeutics, Inc., announced today that the U.S. FDA has cleared the first prescription digital therapeutic intended for the treatment of major depressive disorder (MDD) symptoms as an adjunct to clinician-managed outpatient care for adult patients with MDD age 22 years and older who are on antidepressant medication. This marks an exciting breakthrough in the treatment of MDD symptoms designed to help enhance cognitive control of emotion through a combination of clinically-validated cognitive emotional brain training exercises and brief therapeutic lessons. Learn more here: https://lnkd.in/eKM5StYc #DefyLimitation

Depression is debilitating and can be life threatening. With all the spending on mental health, pharmaceutical treatments and psychological interventions, our mental health on a global scale continues to suffer. Better treatments are needed and these results that persist from MindBio Therapeutics clinical trials are very promising for the future enhancement of mental health treatments. With a lot more work to do, its also very good news for two currently dosing Phase 2B clinical trials underway MindBio Therapeutics.